98 related articles for article (PubMed ID: 8331940)
1. Immunotherapy and whole-body hyperthermia as combined modality treatment of a subcutaneous murine sarcoma.
Geehan DM; Fabian DF; Lefor AT
J Surg Oncol; 1993 Jul; 53(3):180-3. PubMed ID: 8331940
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor alpha mediates the antitumor effect of combined interleukin-2 and whole body hyperthermia.
Fritz KL; Koziol S; Fabian DF; Lefor AT
J Surg Res; 1996 Jan; 60(1):55-60. PubMed ID: 8592432
[TBL] [Abstract][Full Text] [Related]
3. Combined local hyperthermia and immunotherapy treatment of an experimental subcutaneous murine melanoma.
Geehan DM; Fabian DF; Lefor AT
J Surg Oncol; 1995 May; 59(1):35-9. PubMed ID: 7745975
[TBL] [Abstract][Full Text] [Related]
4. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
5. Combined hyperthermia and immunotherapy treatment of multiple pulmonary metastases in mice.
Strauch ED; Fabian DF; Turner J; Lefor AT
Surg Oncol; 1994 Feb; 3(1):45-52. PubMed ID: 8186870
[TBL] [Abstract][Full Text] [Related]
6. Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide.
Silagi S; Schaefer AE
J Biol Response Mod; 1986 Oct; 5(5):411-22. PubMed ID: 3490544
[TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
8. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
Rosenberg SA; Mulé JJ
Surgery; 1985 Sep; 98(3):437-44. PubMed ID: 3898451
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of antitumor response to sarcoma 45 in rats by combination of whole-body hyperthermia and interleukin-2.
Potapnev MP; Istomin YP; Ismail-zade RS; Zhavrid EA
Eksp Onkol; 2004 Mar; 26(1):67-70. PubMed ID: 15112583
[TBL] [Abstract][Full Text] [Related]
11. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
12. Extracorporeal whole body hyperthermia treatments for HIV infection and AIDS.
Ash SR; Steinhart CR; Curfman MF; Gingrich CH; Sapir DA; Ash EL; Fausset JM; Yatvin MB
ASAIO J; 1997; 43(5):M830-8. PubMed ID: 9360163
[TBL] [Abstract][Full Text] [Related]
13. Effect of whole-body hyperthermia on AIDS patients with Kaposi's sarcoma: a pilot study.
Steinhart CR; Ash SR; Gingrich C; Sapir D; Keeling GN; Yatvin MB
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Mar; 11(3):271-81. PubMed ID: 8603263
[TBL] [Abstract][Full Text] [Related]
14. Chemoimmunotherapy of MC-induced mouse sarcomas with human recombinant interleukin 2 and cyclophosphamide: age-dependent decline of the therapeutic efficacy.
Símová J; Bubeník J; Voitenok NN; Gren E
Folia Biol (Praha); 1989; 35(3):137-42. PubMed ID: 2789150
[TBL] [Abstract][Full Text] [Related]
15. Lymphocyte migration to tumors after hyperthermia and immunotherapy.
Midis GP; Fabian DF; Lefor AT
J Surg Res; 1992 May; 52(5):530-6. PubMed ID: 1619922
[TBL] [Abstract][Full Text] [Related]
16. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
Mulé JJ; Shu S; Rosenberg SA
J Immunol; 1985 Jul; 135(1):646-52. PubMed ID: 3889158
[TBL] [Abstract][Full Text] [Related]
17. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2).
Jürgenliemk-Schulz IM; Renes IB; Rutgers DH; Everse LA; Bernsen MR; Den Otter W; Battermann JJ
Radiat Oncol Investig; 1997; 5(2):54-61. PubMed ID: 9303058
[TBL] [Abstract][Full Text] [Related]
19. Local hyperthermia abrogates the anti-immunotherapeutic effect of interleukin-8.
Geehan DM; Fabian DF; Lefor AT
J Surg Oncol; 1994 Jun; 56(2):102-6. PubMed ID: 8007673
[TBL] [Abstract][Full Text] [Related]
20. Interaction of SR-4233 with hyperthermia and radiation in the FSaIIC murine fibrosarcoma tumor system in vitro and in vivo.
Herman TS; Teicher BA; Coleman CN
Cancer Res; 1990 Aug; 50(16):5055-9. PubMed ID: 2379171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
